The Cigna Group

CI: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$133.00ZmqmzyJmfnrzqj

Cigna Turns in Solid Q4 and 2023 Guidance; No Fair Value Estimate Change

Narrow-moat Cigna turned in strong fourth-quarter results that allowed the firm to exceed our expectations for 2022 a bit. However, that mild outperformance combined with 2023 guidance that looks roughly in line with our expectations was not enough to change our $321 fair value estimate. Shares appear about fairly valued, to us.

Sponsor Center